دورية أكاديمية
أعرض في EDS

Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model.

التفاصيل البيبلوغرافية
العنوان: Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model.
المؤلفون: Berkson JD; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Wate CE; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Allen GB; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Schubert AM; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Dunbar KE; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Coryell MP; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Sava RL; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Gao Y; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Viral Products, Laboratory of Pediatric and Respiratory Viral Diseases, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Hastie JL; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Smith EM; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Kenneally CR; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Zimmermann SK; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA., Carlson PE Jr; Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Bacterial Parasitic and Allergenic Products, Laboratory of Mucosal Pathogens and Cellular Immunology, 10903 New Hampshire Ave, Silver Spring, MD, 20832, USA. paul.carlson@fda.hhs.gov.
المصدر: Nature communications [Nat Commun] 2024 Apr 06; Vol. 15 (1), pp. 2993. Date of Electronic Publication: 2024 Apr 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: Bacteriophages*/physiology , Vancomycin-Resistant Enterococci*, Humans ; Animals ; Mice ; Vancomycin/pharmacology ; Disease Models, Animal ; Myoviridae/physiology ; Anti-Bacterial Agents/pharmacology
مستخلص: Bacteriophage therapy is a promising approach to address antimicrobial infections though questions remain regarding the impact of the immune response on clinical effectiveness. Here, we develop a mouse model to assess phage treatment using a cocktail of five phages from the Myoviridae and Siphoviridae families that target Vancomycin-Resistant Enterococcus gut colonization. Phage treatment significantly reduces fecal bacterial loads of Vancomycin-Resistant Enterococcus. We also characterize immune responses elicited following administration of the phage cocktail. While minimal innate responses are observed after phage administration, two rounds of treatment induces phage-specific neutralizing antibodies and accelerate phage clearance from tissues. Interestingly, the myophages in our cocktail induce a more robust neutralizing antibody response than the siphophages. This anti-phage immunity reduces the effectiveness of the phage cocktail in our murine model. Collectively, this study shows phage-specific immune responses may be an important consideration in the development of phage cocktails for therapeutic use.
(© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
References: Curr Opin HIV AIDS. 2009 Sep;4(5):388-93. (PMID: 20048702)
Infect Immun. 2019 Jun 20;87(7):. (PMID: 31010813)
Virology. 2011 Dec 20;421(2):141-8. (PMID: 22018785)
Front Microbiol. 2021 Feb 11;11:599906. (PMID: 33643225)
Antimicrob Agents Chemother. 2017 Sep 22;61(10):. (PMID: 28807909)
Front Immunol. 2019 Nov 14;10:2607. (PMID: 31803179)
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9351-6. (PMID: 27469164)
Virusdisease. 2021 Mar;32(1):38-45. (PMID: 33969154)
Annu Rev Immunol. 2021 Apr 26;39:695-718. (PMID: 33646857)
J Wound Care. 2009 Jun;18(6):237-8, 240-3. (PMID: 19661847)
J Mol Biol. 2010 Jan 29;395(4):728-41. (PMID: 19835886)
J Immunol. 2018 May 1;200(9):3037-3044. (PMID: 29685950)
Open Forum Infect Dis. 2020 Aug 27;7(9):ofaa389. (PMID: 33005701)
Cell Res. 2020 Jun;30(6):492-506. (PMID: 32433595)
Antimicrob Agents Chemother. 2021 Mar 1;65(5):. (PMID: 33649110)
Clin Microbiol Rev. 2019 Jan 16;32(2):. (PMID: 30651225)
Cell Host Microbe. 2019 Feb 13;25(2):285-299.e8. (PMID: 30763538)
Curr Opin HIV AIDS. 2017 May;12(3):209-215. (PMID: 28422785)
Clin Infect Dis. 2018 Aug 31;67(6):905-912. (PMID: 29718144)
AIDS. 2000 Mar 10;14(4):F55-62. (PMID: 10770533)
J Am Med Dir Assoc. 2020 Dec;21(12):1937-1943.e2. (PMID: 32553489)
J Clin Invest. 2010 Dec;120(12):4332-41. (PMID: 21099116)
Evol Med Public Health. 2018 Mar 08;2018(1):60-66. (PMID: 29588855)
Cell Host Microbe. 2021 Mar 10;29(3):334-346. (PMID: 33705705)
Phage (New Rochelle). 2020 Jun 1;1(2):91-99. (PMID: 36147897)
BMC Genomics. 2015 Jan 22;16:7. (PMID: 25608871)
Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
J Infect Dis. 2023 Feb 1;227(3):311-316. (PMID: 36082999)
Lab Anim. 2019 Jun;53(3):232-243. (PMID: 31096878)
J Virol. 2014 Nov;88(21):12551-7. (PMID: 25142581)
J Aerosol Med Pulm Drug Deliv. 2008 Dec;21(4):351-60. (PMID: 18800880)
Structure. 1999 Oct 15;7(10):1213-22. (PMID: 10545330)
Clin Infect Dis. 2023 Jan 6;76(1):103-112. (PMID: 35676823)
Sci Rep. 2015 Oct 06;5:14802. (PMID: 26440922)
Front Microbiol. 2019 Jul 25;10:1704. (PMID: 31402904)
Clin Infect Dis. 2017 Jul 15;65(2):208-215. (PMID: 28369261)
Bioinformatics. 2019 Nov 1;35(22):4537-4542. (PMID: 31329826)
Antimicrob Agents Chemother. 2005 Jul;49(7):2874-8. (PMID: 15980363)
Arch Virol. 2001;146(5):843-57. (PMID: 11448025)
Cell. 2022 Aug 4;185(16):2879-2898.e24. (PMID: 35931020)
Virus Evol. 2020 Dec 30;7(1):veaa100. (PMID: 33505708)
J Mol Biol. 1992 Dec 5;228(3):870-84. (PMID: 1469720)
Front Microbiol. 2016 Oct 24;7:1681. (PMID: 27822205)
Immunity. 2018 Aug 21;49(2):211-224. (PMID: 30134201)
Future Microbiol. 2017 Feb;12:109-117. (PMID: 27643529)
Nature. 2019 Nov;575(7783):505-511. (PMID: 31723265)
J Antimicrob Chemother. 2004 Apr;53(4):626-30. (PMID: 14973150)
Nat Med. 2021 Aug;27(8):1357-1361. (PMID: 34239133)
Med Res Rev. 2019 Sep;39(5):2000-2025. (PMID: 30887551)
Clin Ther. 2023 Aug;45(8):797-801. (PMID: 37442654)
J Exp Med. 1943 Sep 1;78(3):161-8. (PMID: 19871319)
Int J Hyg Environ Health. 2022 Jul;244:114006. (PMID: 35841823)
Cell. 2022 May 26;185(11):1860-1874.e12. (PMID: 35568033)
Infect Immun. 2019 May 21;87(6):. (PMID: 30936157)
Clin Otolaryngol. 2009 Aug;34(4):349-57. (PMID: 19673983)
Cell. 2021 Feb 18;184(4):1098-1109.e9. (PMID: 33606979)
Pharmaceuticals (Basel). 2021 Feb 28;14(3):. (PMID: 33670836)
BMJ Glob Health. 2019 Apr 11;4(2):e001315. (PMID: 31139449)
Can Fam Physician. 2017 Jul;63(7):512-520. (PMID: 28701438)
Nature. 2016 Apr 28;532(7600):512-6. (PMID: 27096360)
Viruses. 2015 Aug 20;7(8):4783-99. (PMID: 26308042)
Sci Total Environ. 2022 Feb 10;807(Pt 2):150873. (PMID: 34634340)
J Glob Antimicrob Resist. 2019 Mar;16:36-47. (PMID: 30149193)
Clin Microbiol Infect. 2023 Jun;29(6):702-709. (PMID: 36736661)
Front Immunol. 2021 Jun 14;12:639570. (PMID: 34194425)
Viruses. 2023 Apr 21;15(4):. (PMID: 37113000)
Viruses. 2021 Sep 07;13(9):. (PMID: 34578366)
Cell Host Microbe. 2017 Dec 13;22(6):801-808.e3. (PMID: 29174401)
Viruses. 2020 Mar 01;12(3):. (PMID: 32121563)
المشرفين على المادة: 6Q205EH1VU (Vancomycin)
0 (Anti-Bacterial Agents)
تواريخ الأحداث: Date Created: 20240406 Date Completed: 20240408 Latest Revision: 20240409
رمز التحديث: 20240409
مُعرف محوري في PubMed: PMC10998888
DOI: 10.1038/s41467-024-47192-w
PMID: 38582763
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-024-47192-w